Is US Biotech Still the Center of Gravity? Or Are Global Markets Rewriting the Rules?

For decades, the US has been the undisputed engine of biotech innovation'dominating venture capital flows, clinical development, and the commercialization of breakthrough therapies. But as costs rise and competition intensifies, a new question is emerging across the industry: can US biotech still scale without looking outward? At the same time, emerging markets'including the Middle East'are no longer passive destinations for innovation. They are actively competing to become strategic partners in clinical development, manufacturing, and investment, offering capital, infrastructure, and access to rapidly evolving healthcare systems. This panel will challenge conventional thinking on global biotech expansion, exploring whether US companies are strategically expanding'or being forced to globalize'and how this shift is reshaping investor behavior, deal flow, and the future geography of advanced therapies. Key themes: Is US biotech still the dominant global growth engine'or just one of many hubs? Are emerging markets becoming essential partners or opportunistic alternatives? What is truly driving cross-border expansion: strategy, capital efficiency, or necessity? How will global investment flows shift as biotech becomes increasingly decentralized?